Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02186834 · ClinicalTrials.gov registry record · Phase 1
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02186834 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 28 participants.
The verdict
NCT02186834, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the recommended doses of selinexor in combination with liposomal doxorubicin and dexamethasone for patients with relapsed and refractory myeloma. In addition, the study will assess whether this combination with effective for patients with multiple myeloma.
Interventions
- DRUG Selinexor
- DRUG Dexamethasone
- DRUG Liposomal doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2014-09-23 |
| Est. Completion | 2018-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02186834
The ClinicalTrials.gov registry entry for NCT02186834 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Selinexor is the first listed.
NCT02186834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02186834 about?
NCT02186834 is a clinical study titled "Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma". The main purpose of this study is to determine the recommended doses of selinexor in combination with liposomal doxorubicin and dexamethasone for patients with relapsed and refractory myeloma. In addition, the study will assess whether this combination with effective for patients with multiple myelo...
What is the current status of trial NCT02186834?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2014-09-23. Estimated completion is 2018-03-14.
What interventions are being tested in trial NCT02186834?
The interventions under investigation include: Selinexor (DRUG), Dexamethasone (DRUG), Liposomal doxorubicin (DRUG).
Who is sponsoring clinical trial NCT02186834?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.